Doacs And "Newer" Hemophilia Therapies In Covid-19: Reply

We would like to thank the authors for their insightful thoughts on the consideration of anticoagulants and treatment for haemophilia A and B during the COVID-19 pandemic. They highlight some important practical points which certainly should be adopted by the thrombosis and haemostasis community in the current situation of restricted mobility, which reduces the possibility for patients to access general practitioners and hospitals.